Cervical adenocarcinoma

Summary

Cervical adenocarcinoma (MONDO:0005153) is a disease (an umbrella term covering 10 Mondo subtypes) with 1 cohort gene and 63 clinical trials. Molecularly, AURKA Overexpression is associated with resistance to Paclitaxel in Cervical Adenocarcinoma (CIViC Level D). Top therapeutic interventions include cisplatin, methylene blue cation, and topotecan.

At a glance

• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Umbrella term: 10 Mondo subtypes
• Cohort genes: 1
• Clinical trials: 63
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

Epidemiology

Prevalence records

24 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	1.01	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.762	Austria	Validated
Annual incidence	1-9 / 1 000 000	0.966	Belgium	Validated
Annual incidence	1-9 / 1 000 000	0.968	Croatia	Validated
Annual incidence	1-9 / 1 000 000	0.85	Estonia	Validated
Annual incidence	1-9 / 1 000 000	0.899	Finland	Validated
Annual incidence	1-9 / 1 000 000	0.987	Germany	Validated
Annual incidence	1-9 / 1 000 000	0.789	Ireland	Validated
Annual incidence	1-9 / 1 000 000	0.734	Italy	Validated
Annual incidence	1-9 / 1 000 000	0.774	Latvia	Validated
Annual incidence	1-9 / 1 000 000	0.471	Malta	Validated
Annual incidence	1-9 / 1 000 000	0.766	Poland	Validated
Annual incidence	1-9 / 1 000 000	0.868	Spain	Validated
Annual incidence	1-9 / 1 000 000	0.738	Switzerland	Validated
Annual incidence	1-9 / 1 000 000	0.765	Netherlands	Validated
Annual incidence	1-9 / 1 000 000	0.918	United Kingdom	Validated
Annual incidence	1-9 / 100 000	1.108	Bulgaria	Validated
Annual incidence	1-9 / 100 000	1.108	Czech Republic	Validated
Annual incidence	1-9 / 100 000	1.065	Iceland	Validated
Annual incidence	1-9 / 100 000	1.118	Lithuania	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical adenocarcinoma
Mondo ID	MONDO:0005153
EFO	EFO:0001416
Orphanet	213772
DOID	DOID:3702
ICD-11	261293318
NCIT	C4029
SNOMED CT	254887002
UMLS	C0279672
MedGen	79024
GARD	0020488
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	no

Also known as: adenocarcinoma - cervix · adenocarcinoma of cervix · adenocarcinoma of cervix uteri · adenocarcinoma of the cervix · adenocarcinoma of the cervix uteri · adenocarcinoma of the uterine cervix · adenocarcinoma of uterine cervix · cervical adenocarcinoma · cervix adenocarcinoma · cervix uteri adenocarcinoma · uterine cervix adenocarcinoma

Data availability: 19 cell lines · 20 intOGen driver records.

Disease family

An umbrella term covering 10 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › cervical adenocarcinoma

Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma

Subtypes (10): endocervical adenocarcinoma, uterine ligament adenocarcinoma, cervical mucinous adenocarcinoma, Wolffian duct adenocarcinoma, cervical serous adenocarcinoma, cervical endometrioid adenocarcinoma, early invasive cervical adenocarcinoma, cervical adenoid cystic carcinoma, cervical adenosquamous carcinoma, cervical clear cell adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
AURKA	HGNC:11393	ENSG00000087586	O14965	Aurora kinase A	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
AURKA	Aurora kinase A	Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
AURKA	Kinase	yes	2.7.11.1	Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
oocyte	1
secondary oocyte	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
AURKA	236	ubiquitous	marker	oocyte, secondary oocyte, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
AURKA	6,376

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
AURKA	O14965	193

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 24. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Interaction between PHLDA1 and AURKA	1	5710.0×	0.004	AURKA
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	1	601.0×	0.013	AURKA
TP53 Regulates Transcription of Cell Cycle Genes	1	543.8×	0.013	AURKA
APC/C-mediated degradation of cell cycle proteins	1	335.9×	0.013	AURKA
Regulation of mitotic cell cycle	1	335.9×	0.013	AURKA
SUMOylation of DNA replication proteins	1	248.3×	0.013	AURKA
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis	1	248.3×	0.013	AURKA
SUMO E3 ligases SUMOylate target proteins	1	178.4×	0.013	AURKA
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1	1	170.4×	0.013	AURKA
SUMOylation	1	163.1×	0.013	AURKA
AURKA Activation by TPX2	1	152.3×	0.013	AURKA
Regulation of TP53 Activity	1	132.8×	0.013	AURKA
Regulation of PLK1 Activity at G2/M Transition	1	126.9×	0.013	AURKA
Mitotic G2-G2/M phases	1	126.9×	0.013	AURKA
G2/M Transition	1	126.9×	0.013	AURKA
Regulation of TP53 Activity through Phosphorylation	1	117.7×	0.013	AURKA
Transcriptional Regulation by TP53	1	62.1×	0.023	AURKA
Cell Cycle, Mitotic	1	48.2×	0.028	AURKA
Cell Cycle	1	36.0×	0.035	AURKA
RNA Polymerase II Transcription	1	22.5×	0.053	AURKA
Post-translational protein modification	1	19.2×	0.060	AURKA
Gene expression (Transcription)	1	17.8×	0.061	AURKA
Generic Transcription Pathway	1	15.1×	0.069	AURKA
Metabolism of proteins	1	12.4×	0.081	AURKA

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of oocyte maturation	1	5617.3×	0.003	AURKA
spindle assembly involved in female meiosis I	1	3370.4×	0.003	AURKA
cilium disassembly	1	3370.4×	0.003	AURKA
mitotic centrosome separation	1	2808.7×	0.003	AURKA
regulation of centrosome cycle	1	1872.4×	0.003	AURKA
regulation of G2/M transition of mitotic cell cycle	1	1296.3×	0.004	AURKA
spindle organization	1	991.3×	0.004	AURKA
centrosome localization	1	887.0×	0.004	AURKA
positive regulation of mitochondrial fission	1	766.0×	0.004	AURKA
anterior/posterior axis specification	1	732.7×	0.004	AURKA
protein localization to centrosome	1	674.1×	0.004	AURKA
negative regulation of protein binding	1	624.1×	0.004	AURKA
positive regulation of mitotic nuclear division	1	543.6×	0.004	AURKA
neuron projection extension	1	526.6×	0.004	AURKA
liver regeneration	1	510.7×	0.004	AURKA
peptidyl-serine phosphorylation	1	495.6×	0.004	AURKA
positive regulation of mitotic cell cycle	1	468.1×	0.004	AURKA
regulation of cytokinesis	1	421.3×	0.004	AURKA
regulation of signal transduction by p53 class mediator	1	383.0×	0.004	AURKA
G2/M transition of mitotic cell cycle	1	312.1×	0.005	AURKA
mitotic spindle organization	1	271.8×	0.006	AURKA
response to wounding	1	221.7×	0.007	AURKA
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	1	210.7×	0.007	AURKA
protein autophosphorylation	1	145.3×	0.009	AURKA
mitotic cell cycle	1	133.8×	0.010	AURKA
regulation of protein stability	1	125.8×	0.010	AURKA
negative regulation of gene expression	1	69.1×	0.017	AURKA
protein phosphorylation	1	68.0×	0.017	AURKA
proteasome-mediated ubiquitin-dependent protein catabolic process	1	52.2×	0.021	AURKA
cell division	1	46.2×	0.023	AURKA

Therapeutics

Drugs indicated for this disease

1 approved, 11 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Bevacizumab	Approved (phase 4)
Cadonilimab	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Epoetin Alfa	Phase 3 (in late-stage trials)
Gemcitabine	Phase 3 (in late-stage trials)
Irinotecan	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Pembrolizumab	Phase 3 (in late-stage trials)
Pemetrexed	Phase 3 (in late-stage trials)
Tirapazamine	Phase 3 (in late-stage trials)
Topotecan	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bintrafusp Alfa, Curcumin, Ipilimumab, Letrozole, Metformin, Nintedanib, Nivolumab, Sintilimab, Tamoxifen, Tislelizumab, Toripalimab.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
AURKA	INAMRINONE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
AURKA	65	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
INAMRINONE	4	AURKA
FEDRATINIB	4	AURKA
AXITINIB	4	AURKA
SORAFENIB	4	AURKA
NICLOSAMIDE	4	AURKA
ENTRECTINIB	4	AURKA
FOSTAMATINIB	4	AURKA
CABOZANTINIB	4	AURKA
GILTERITINIB	4	AURKA
BRIGATINIB	4	AURKA
UPADACITINIB	4	AURKA
SULFADIAZINE	4	AURKA
PAZOPANIB	4	AURKA
DOXORUBICIN	4	AURKA
SUNITINIB	4	AURKA
DASATINIB	4	AURKA
ERLOTINIB	4	AURKA
CRIZOTINIB	4	AURKA
MIDOSTAURIN	4	AURKA
LINIFANIB	3	AURKA
ORANTINIB	3	AURKA
DEFACTINIB	3	AURKA
BARASERTIB	3	AURKA
ALISERTIB	3	AURKA
LESTAURTINIB	3	AURKA
FORETINIB	2	AURKA
AZD-1480	2	AURKA
MK-2461	2	AURKA
CENISERTIB	2	AURKA
ILORASERTIB	2	AURKA

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
AURKA	1,500	Binding:1483, Functional:10, ADMET:7

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
AURKA	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
AURKA	1,500

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
INAMRINONE	4	AURKA
FEDRATINIB	4	AURKA
AXITINIB	4	AURKA
SORAFENIB	4	AURKA
NICLOSAMIDE	4	AURKA
ENTRECTINIB	4	AURKA
FOSTAMATINIB	4	AURKA
CABOZANTINIB	4	AURKA
GILTERITINIB	4	AURKA
BRIGATINIB	4	AURKA
UPADACITINIB	4	AURKA
SULFADIAZINE	4	AURKA
PAZOPANIB	4	AURKA
DOXORUBICIN	4	AURKA
SUNITINIB	4	AURKA
DASATINIB	4	AURKA
ERLOTINIB	4	AURKA
CRIZOTINIB	4	AURKA
MIDOSTAURIN	4	AURKA
LINIFANIB	3	AURKA
ORANTINIB	3	AURKA
DEFACTINIB	3	AURKA
BARASERTIB	3	AURKA
ALISERTIB	3	AURKA
LESTAURTINIB	3	AURKA
FORETINIB	2	AURKA
AZD-1480	2	AURKA
MK-2461	2	AURKA
CENISERTIB	2	AURKA
ILORASERTIB	2	AURKA

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	AURKA
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 63.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	25
PHASE1	13
Not specified	13
PHASE3	8
PHASE1/PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02466971	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
NCT07061977	PHASE3	RECRUITING	Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT00017004	PHASE3	COMPLETED	Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
NCT00064077	PHASE3	COMPLETED	Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
NCT00262821	PHASE3	TERMINATED	Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
NCT00803062	PHASE3	COMPLETED	Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
NCT01101451	PHASE3	COMPLETED	Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
NCT01414608	PHASE3	COMPLETED	Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
NCT02257528	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT06543576	PHASE1/PHASE2	RECRUITING	External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
NCT06654011	PHASE2	RECRUITING	IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
NCT06783153	PHASE1/PHASE2	NOT_YET_RECRUITING	Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
NCT06805864	PHASE2	NOT_YET_RECRUITING	Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
NCT07141186	PHASE2	NOT_YET_RECRUITING	QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
NCT07153952	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	RT for Adenocarcinoma/Adenosquamous Carcinoma
NCT07276360	PHASE2	RECRUITING	Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
NCT00039442	PHASE2	COMPLETED	Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00057863	PHASE2	COMPLETED	Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
NCT00217633	PHASE2	COMPLETED	Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
NCT00309959	PHASE2	COMPLETED	ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00369122	PHASE2	COMPLETED	Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
NCT00389974	PHASE2	COMPLETED	Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
NCT00416455	PHASE1/PHASE2	COMPLETED	Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
NCT00559377	PHASE2	COMPLETED	FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
NCT00924066	PHASE2	TERMINATED	Ixabepilone to Treat Cervical Cancer
NCT01026792	PHASE2	COMPLETED	Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
NCT01266447	PHASE2	COMPLETED	Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01266460	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01267253	PHASE2	COMPLETED	Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01639625	PHASE2	COMPLETED	Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application
NCT01693783	PHASE2	COMPLETED	Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
NCT02562729	PHASE2	COMPLETED	Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
NCT02868892	PHASE2	TERMINATED	A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
NCT02880007	PHASE2	COMPLETED	Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer
NCT02921269	PHASE2	COMPLETED	Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
NCT03834571	PHASE2	WITHDRAWN	Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
NCT02595879	PHASE1	ACTIVE_NOT_RECRUITING	Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
NCT07020117	PHASE1	RECRUITING	A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07454642	PHASE1	RECRUITING	AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	21
METHYLENE BLUE CATION	4	3
TOPOTECAN	4	3
FLUDEOXYGLUCOSE F 18	4	2
EPOETIN ALFA	4	1
GEMCITABINE HYDROCHLORIDE	4	1
ISOSULFAN BLUE	4	1
SUNITINIB MALATE	4	1
TECHNETIUM TC 99M SULFUR COLLOID	4	1
TEMSIROLIMUS	4	1
VINORELBINE TARTRATE	4	1
VELIPARIB	3	4
TRIAPINE	3	2
BRIVANIB ALANINATE	3	1
FERUMOXTRAN-10	3	1
TIRAPAZAMINE	3	1
IFEBEMTINIB	2	1
CHEMBL3109278	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
AURKA Overexpression	Paclitaxel	Resistance	CIViC D	EID457